Management and grading of EGFR inhibitor-induced cutaneous toxicity.

2.50
Hdl Handle:
http://hdl.handle.net/10541/621027
Title:
Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Authors:
Beech, Janette; Germetaki, Theodora; Judge, M; Paton, Nina; Collins, Joanne; Garbutt, Abigail; Braun, Michael S; Fenwick, J; Saunders, Mark P
Abstract:
Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.
Affiliation:
Department of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UK
Citation:
Management and grading of EGFR inhibitor-induced cutaneous toxicity. 2018 Future Oncol
Journal:
Future Oncology
Issue Date:
4-May-2018
URI:
http://hdl.handle.net/10541/621027
DOI:
10.2217/fon-2018-0187
PubMed ID:
29727211
Type:
Article
Language:
en
ISSN:
1744-8301
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBeech, Janetteen
dc.contributor.authorGermetaki, Theodoraen
dc.contributor.authorJudge, Men
dc.contributor.authorPaton, Ninaen
dc.contributor.authorCollins, Joanneen
dc.contributor.authorGarbutt, Abigailen
dc.contributor.authorBraun, Michael Sen
dc.contributor.authorFenwick, Jen
dc.contributor.authorSaunders, Mark Pen
dc.date.accessioned2018-06-04T09:41:36Z-
dc.date.available2018-06-04T09:41:36Z-
dc.date.issued2018-05-04-
dc.identifier.citationManagement and grading of EGFR inhibitor-induced cutaneous toxicity. 2018 Future Oncolen
dc.identifier.issn1744-8301-
dc.identifier.pmid29727211-
dc.identifier.doi10.2217/fon-2018-0187-
dc.identifier.urihttp://hdl.handle.net/10541/621027-
dc.description.abstractCutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.en
dc.language.isoenen
dc.rightsArchived with thanks to Future oncology (London, England)en
dc.titleManagement and grading of EGFR inhibitor-induced cutaneous toxicity.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UKen
dc.identifier.journalFuture Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.